Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: A single center experience

Ashok Jain, Rajeev Sharma, Charlotte Ryan, Saman Safadjou, Randeep Kashyap, Parvez Mantry, Benedict Maliakkal, Mark Orloff

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: Recurrence of hepatitis C virus (HCV) in hepatic allograft is a major concern after successful liver transplant (LTx). Aim: To examine the response rate to pegylated interferon (PEG-IFN) and ribavirin in post-LTx patients with HCV recurrence. Patients and methods: Between January 2003 and September 2006, 60 patients with biopsy proven HCV recurrence (46 males and 14 females) received PEG-IFN 2a (n = 40) or IFN 2b (n = 20) with ribavirin. All patients were followed until July 2007. Results: Fourteen patients (23.3%) tolerated antiviral therapy for less than six months and 10 (16.7%) discontinued therapy between six and 11 months. PEG-IFN dose was reduced in 21 (35%) patients and ribavirin dose was reduced in 16 (26.7%) patients. Overall, 55% patients achieved end of treatment response (EOT) and 35% sustained virological response (SVR). Mean Hepatitis Activity Index and Fibrosis Score pre-therapy was 5.8 ± 1.9 and 1.7 ± 1.3 and post-therapy, it was 4.4 ± 2.1 and 2.4 ± 1.6, respectively. Overall, three yr patient and graft survival was 73.9% and 69.2%, respectively. The patients with SVR had significantly lower viral load compared with other groups (p = 0.028). Conclusion: PEG-IFN and ribavirin therapy achieved 55% EOT and 35% SVR; 60% patients tolerated therapy. Biochemical response was observed in all groups of patients irrespective of virological response.

Original languageEnglish (US)
Pages (from-to)104-111
Number of pages8
JournalClinical Transplantation
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Virus Diseases
Hepatitis C
Antiviral Agents
Liver
Ribavirin
Interferons
Therapeutics
Hepacivirus
Recurrence
Transplant Recipients
Graft Survival
Viral Load
Hepatitis
Allografts
Fibrosis
Transplants
Biopsy

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Jain, Ashok ; Sharma, Rajeev ; Ryan, Charlotte ; Safadjou, Saman ; Kashyap, Randeep ; Mantry, Parvez ; Maliakkal, Benedict ; Orloff, Mark. / Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection : A single center experience. In: Clinical Transplantation. 2010 ; Vol. 24, No. 1. pp. 104-111.
@article{19b6beda221b4cd5884455f179724a2f,
title = "Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: A single center experience",
abstract = "Introduction: Recurrence of hepatitis C virus (HCV) in hepatic allograft is a major concern after successful liver transplant (LTx). Aim: To examine the response rate to pegylated interferon (PEG-IFN) and ribavirin in post-LTx patients with HCV recurrence. Patients and methods: Between January 2003 and September 2006, 60 patients with biopsy proven HCV recurrence (46 males and 14 females) received PEG-IFN 2a (n = 40) or IFN 2b (n = 20) with ribavirin. All patients were followed until July 2007. Results: Fourteen patients (23.3{\%}) tolerated antiviral therapy for less than six months and 10 (16.7{\%}) discontinued therapy between six and 11 months. PEG-IFN dose was reduced in 21 (35{\%}) patients and ribavirin dose was reduced in 16 (26.7{\%}) patients. Overall, 55{\%} patients achieved end of treatment response (EOT) and 35{\%} sustained virological response (SVR). Mean Hepatitis Activity Index and Fibrosis Score pre-therapy was 5.8 ± 1.9 and 1.7 ± 1.3 and post-therapy, it was 4.4 ± 2.1 and 2.4 ± 1.6, respectively. Overall, three yr patient and graft survival was 73.9{\%} and 69.2{\%}, respectively. The patients with SVR had significantly lower viral load compared with other groups (p = 0.028). Conclusion: PEG-IFN and ribavirin therapy achieved 55{\%} EOT and 35{\%} SVR; 60{\%} patients tolerated therapy. Biochemical response was observed in all groups of patients irrespective of virological response.",
author = "Ashok Jain and Rajeev Sharma and Charlotte Ryan and Saman Safadjou and Randeep Kashyap and Parvez Mantry and Benedict Maliakkal and Mark Orloff",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1399-0012.2009.00961.x",
language = "English (US)",
volume = "24",
pages = "104--111",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1",

}

Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection : A single center experience. / Jain, Ashok; Sharma, Rajeev; Ryan, Charlotte; Safadjou, Saman; Kashyap, Randeep; Mantry, Parvez; Maliakkal, Benedict; Orloff, Mark.

In: Clinical Transplantation, Vol. 24, No. 1, 01.01.2010, p. 104-111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection

T2 - A single center experience

AU - Jain, Ashok

AU - Sharma, Rajeev

AU - Ryan, Charlotte

AU - Safadjou, Saman

AU - Kashyap, Randeep

AU - Mantry, Parvez

AU - Maliakkal, Benedict

AU - Orloff, Mark

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction: Recurrence of hepatitis C virus (HCV) in hepatic allograft is a major concern after successful liver transplant (LTx). Aim: To examine the response rate to pegylated interferon (PEG-IFN) and ribavirin in post-LTx patients with HCV recurrence. Patients and methods: Between January 2003 and September 2006, 60 patients with biopsy proven HCV recurrence (46 males and 14 females) received PEG-IFN 2a (n = 40) or IFN 2b (n = 20) with ribavirin. All patients were followed until July 2007. Results: Fourteen patients (23.3%) tolerated antiviral therapy for less than six months and 10 (16.7%) discontinued therapy between six and 11 months. PEG-IFN dose was reduced in 21 (35%) patients and ribavirin dose was reduced in 16 (26.7%) patients. Overall, 55% patients achieved end of treatment response (EOT) and 35% sustained virological response (SVR). Mean Hepatitis Activity Index and Fibrosis Score pre-therapy was 5.8 ± 1.9 and 1.7 ± 1.3 and post-therapy, it was 4.4 ± 2.1 and 2.4 ± 1.6, respectively. Overall, three yr patient and graft survival was 73.9% and 69.2%, respectively. The patients with SVR had significantly lower viral load compared with other groups (p = 0.028). Conclusion: PEG-IFN and ribavirin therapy achieved 55% EOT and 35% SVR; 60% patients tolerated therapy. Biochemical response was observed in all groups of patients irrespective of virological response.

AB - Introduction: Recurrence of hepatitis C virus (HCV) in hepatic allograft is a major concern after successful liver transplant (LTx). Aim: To examine the response rate to pegylated interferon (PEG-IFN) and ribavirin in post-LTx patients with HCV recurrence. Patients and methods: Between January 2003 and September 2006, 60 patients with biopsy proven HCV recurrence (46 males and 14 females) received PEG-IFN 2a (n = 40) or IFN 2b (n = 20) with ribavirin. All patients were followed until July 2007. Results: Fourteen patients (23.3%) tolerated antiviral therapy for less than six months and 10 (16.7%) discontinued therapy between six and 11 months. PEG-IFN dose was reduced in 21 (35%) patients and ribavirin dose was reduced in 16 (26.7%) patients. Overall, 55% patients achieved end of treatment response (EOT) and 35% sustained virological response (SVR). Mean Hepatitis Activity Index and Fibrosis Score pre-therapy was 5.8 ± 1.9 and 1.7 ± 1.3 and post-therapy, it was 4.4 ± 2.1 and 2.4 ± 1.6, respectively. Overall, three yr patient and graft survival was 73.9% and 69.2%, respectively. The patients with SVR had significantly lower viral load compared with other groups (p = 0.028). Conclusion: PEG-IFN and ribavirin therapy achieved 55% EOT and 35% SVR; 60% patients tolerated therapy. Biochemical response was observed in all groups of patients irrespective of virological response.

UR - http://www.scopus.com/inward/record.url?scp=74949083503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949083503&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2009.00961.x

DO - 10.1111/j.1399-0012.2009.00961.x

M3 - Article

C2 - 19239480

AN - SCOPUS:74949083503

VL - 24

SP - 104

EP - 111

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1

ER -